Table 1.

Prescription rate by patient number and market share by costs of targeted therapies over time (2004–2013)

	Prescription rate by patient number							Market share by costs
	Number of patients who used antineoplastic agents	Number of patients who used gefitinib	(%)	Number of patients who used erlotinib	(%)	Number of patients who used targeted therapies (gefitinib+erlotinib)	(%)	Cost of antineoplastic agents (US$)	Cost of gefitinib (US$)	(%)	Cost of erlotinib (US$)	(%)	Cost of targeted therapies (gefitinib+erlotinib) (US$)	(%)
2004	4162	228	5.48	0	0.00	228	5.48	14 887 913	5 73 515	3.85	0	0.00	5 73 515	3.85
2005	4876	872	17.88	0	0.00	872	17.88	22 446 991	8 015 889	35.71	0	0.00	8 015 889	35.71
2006	5173	1095	21.17	0	0.00	1095	21.17	27 126 263	10 435 769	38.47	0	0.00	10 435 769	38.47
2007	5909	1413	23.91	499	8.44	1912	32.36	29 531 282	12 265 156	41.53	2 694 918	9.13	14 960 074	50.66
2008	7130	1975	27.70	1418	19.89	3393	47.59	43 162 957	18 784 869	43.52	11 190 711	25.93	29 975 581	69.45
2009	7673	1922	25.05	2090	27.24	4012	52.29	48 988 605	17 276 102	35.27	18 099 806	36.95	35 375 908	72.21
2010	8200	2058	25.10	2445	29.82	4503	54.91	51 384 668	16 242 224	31.61	20 207 860	39.33	36 450 084	70.94
2011	10 254	3440	33.55	2754	26.86	6194	60.41	58 115 193	20 942 858	36.04	19 298 723	33.21	40 241 581	69.24
2012	12 621	5011	39.70	3029	24.00	8040	63.70	76 127 283	36 628 520	48.11	17 785 455	23.36	54 413 975	71.48
2013	14 597	5558	38.08	2984	20.44	8542	58.52	91 642 044	41 677 315	45.48	15 488 583	16.90	57 165 899	62.38